Published in Kidney Int on March 01, 2005
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant (2010) 2.70
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol (2010) 2.67
Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res (2011) 2.56
Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis (2008) 2.46
Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis (2010) 1.82
Con: Phosphate binders in chronic kidney disease. Nephrol Dial Transplant (2015) 1.72
Habitual physical activity measured by accelerometer and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.71
Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. Am J Nephrol (2010) 1.52
Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol (2009) 1.51
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol (2014) 1.48
Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Ren Nutr (2012) 1.46
Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.36
Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol (2010) 1.31
Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol (2008) 1.18
Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis (2011) 1.17
Vitamin D and kidney disease. Clin J Am Soc Nephrol (2008) 1.16
Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease. Am J Pathol (2011) 1.14
Cost-effectiveness of frequent in-center hemodialysis. J Am Soc Nephrol (2008) 1.13
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int (2009) 1.08
Artificial receptors for the recognition of phosphorylated molecules. Chem Rev (2011) 1.06
Phosphate and cardiovascular disease. Adv Chronic Kidney Dis (2011) 1.06
Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol (2008) 1.04
Identifying best practices in dialysis care: results of cognitive interviews and a national survey of dialysis providers. Clin J Am Soc Nephrol (2008) 1.04
The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant (2009) 1.04
Surgical management of secondary hyperparathyroidism in chronic kidney disease-a consensus report of the European Society of Endocrine Surgeons. Langenbecks Arch Surg (2015) 1.03
Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. PLoS One (2012) 1.03
FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study. Ann Intensive Care (2011) 1.02
Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism. Langenbecks Arch Surg (2012) 1.02
Mechanisms and clinical consequences of vascular calcification. Front Endocrinol (Lausanne) (2012) 1.01
Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis. Perit Dial Int (2014) 1.00
Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant (2011) 1.00
Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant (2013) 0.95
Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol (2013) 0.95
Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol (2009) 0.94
Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost (2010) 0.94
Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients (2013) 0.93
Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance Dialysis. J Am Soc Nephrol (2015) 0.93
Outcomes associated with serum calcium level in men with non-dialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol (2010) 0.92
Bone mineral metabolism and subsequent hospitalization with poor quality of life in dialysis patients. Nephrourol Mon (2014) 0.92
Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone (2014) 0.92
Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2009) 0.91
Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients. Clin J Am Soc Nephrol (2010) 0.91
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol (2013) 0.90
Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodial Int (2015) 0.89
Peritoneal membrane phosphate transport status: a cornerstone in phosphate handling in peritoneal dialysis. Clin J Am Soc Nephrol (2010) 0.88
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant (2008) 0.88
A case report of sevelamer-associated recto-sigmoid ulcers. BMC Gastroenterol (2016) 0.88
Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. J Am Soc Nephrol (2015) 0.87
Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients. J Ren Nutr (2013) 0.86
Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study. BMC Nephrol (2011) 0.86
Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J (2013) 0.86
Combined alkaline phosphatase and phosphorus levels as a predictor of mortality in maintenance hemodialysis patients. Medicine (Baltimore) (2014) 0.85
Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis. J Bone Miner Metab (2014) 0.84
Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? J Am Soc Nephrol (2014) 0.84
Risk Score to Predict 1-Year Mortality after Haemodialysis Initiation in Patients with Stage 5 Chronic Kidney Disease under Predialysis Nephrology Care. PLoS One (2015) 0.84
Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes. Clin J Am Soc Nephrol (2012) 0.84
Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther Adv Chronic Dis (2012) 0.84
Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus (2008) 0.83
Regulatory circuits controlling vascular cell calcification. Cell Mol Life Sci (2012) 0.83
Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Exp Cell Res (2015) 0.82
Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton) (2016) 0.82
Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis. World J Surg (2009) 0.82
Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders. Indian J Pharmacol (2014) 0.82
Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study. BMC Nephrol (2012) 0.82
Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. BMC Nephrol (2013) 0.81
Pharmacology of the phosphate binder, lanthanum carbonate. Ren Fail (2011) 0.81
Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug? Pediatr Nephrol (2010) 0.81
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol (2011) 0.80
CKD-MBD: impact on management of kidney disease. Clin Exp Nephrol (2007) 0.80
A New Data Analysis System to Quantify Associations between Biochemical Parameters of Chronic Kidney Disease-Mineral Bone Disease. PLoS One (2016) 0.80
A Japanese approach for CKD-MBD. Kidney Int Suppl (2011) (2013) 0.79
Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Int Suppl (2011) (2013) 0.79
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Ther Adv Chronic Dis (2011) 0.79
Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin Pharmacol (2014) 0.79
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag (2008) 0.79
Management of phosphorus load in CKD patients. Clin Exp Nephrol (2016) 0.78
Current status of parathyroidectomy for secondary hyperparathyroidism in Japan. NDT Plus (2008) 0.78
Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol (2015) 0.78
Characteristics of the clinical practice patterns of hemodialysis in Japan in consideration of DOPPS and the NKF/DOQI guidelines. Clin Exp Nephrol (2008) 0.78
The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. NDT Plus (2008) 0.78
Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes. Singapore Med J (2015) 0.78
Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000Prime Rep (2014) 0.78
Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D (2013) 0.78
Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients. Am J Nephrol (2016) 0.78
Calcium abnormalities of dialysis patients. J Bone Miner Metab (2006) 0.77
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial. Hemodial Int (2015) 0.77
A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis. Int J Nephrol Renovasc Dis (2014) 0.77
Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? BMC Nephrol (2012) 0.77
Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. PLoS One (2014) 0.77
The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients. PLoS One (2012) 0.77
Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients. Int J Nephrol Renovasc Dis (2014) 0.77
Whole blood versus serum ionized calcium concentrations in dialysis patients. Korean J Intern Med (2014) 0.77
High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease. Nephrol Dial Transplant (2012) 0.77
Usefulness and feasibility of measuring ionized calcium in haemodialysis patients. Clin Kidney J (2015) 0.76
Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis. BMC Nephrol (2013) 0.76
Hyperphosphatemia. The hidden killer in chronic kidney disease. Saudi Med J (2015) 0.75
Efficacy of early treatment with calcimimetics in combination with reduced doses of vitamin d sterols in dialysis patients. NDT Plus (2008) 0.75
The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients. Am J Kidney Dis (2015) 0.75
Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
The survival benefit of liver transplantation. Am J Transplant (2005) 5.08
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2008) 4.72
A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation (2009) 4.45
Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA (2005) 4.16
Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med (2004) 3.96
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis (2015) 3.94
Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int (2003) 3.90
Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol (2006) 3.84
Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int (2002) 3.79
Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. Transplantation (2007) 3.69
Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol (2003) 3.53
A multinational cohort study of in-center daily hemodialysis and patient survival. Kidney Int (2012) 3.47
Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 3.37
The DOPPS Practice Monitor for US dialysis care: trends through December 2011. Am J Kidney Dis (2012) 3.29
Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2006) 3.21
Dialysis outcomes and analysis of practice patterns suggests the dialysis schedule affects day-of-week mortality. Kidney Int (2012) 3.02
Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant (2008) 2.99
Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis (2009) 2.93
Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant (2007) 2.68
Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int (2003) 2.65
Revisiting survival differences by race and ethnicity among hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol (2006) 2.65
Expanded criteria donors for kidney transplantation. Am J Transplant (2003) 2.25
Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int (2002) 2.24
High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int (2008) 2.22
Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol (2010) 2.22
The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol (2002) 2.18
Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int (2002) 2.16
Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int (2004) 2.15
Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs. Kidney Int (2013) 2.14
Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int (2010) 2.10
Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial (2013) 2.07
Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis (2005) 2.05
Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis (2007) 2.03
Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2007) 2.01
Insurance type and minority status associated with large disparities in prelisting dialysis among candidates for kidney transplantation. Clin J Am Soc Nephrol (2008) 1.98
Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.93
Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis (2012) 1.91
Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant (2004) 1.90
Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2013) 1.90
Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int (2005) 1.89
Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2012) 1.88
Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2003) 1.86
Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2007) 1.85
Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis (2004) 1.84
Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 1.83
Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant (2006) 1.82
Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2004) 1.81